[Oral 13-cis-retinoic acid therapy in adenoma sebaceum symmetricum and the most severe forms of acne and rosacea].
Twenty-one patients with severe acne (acne papulopustulosa, acne conglobata, acne cystica), six patients with severe rosacea (rosacea paulopustulosa, rosacea conglobata, rhinophyma), and three patients with tuberous sclerosis were treated with 13-cis-retinoic acid for 6-48 weeks. Most patients had been previously treated with dermabrasion, antibiotics or metronidazole. Dependent on the severeness of the pathological symptoms 13-cis-retinoic acid was administered at a dose of 0.2 to 0.5 mg/kg body weight and was then reduced every 4 weeks. We confirm the sebostatic and antiinflammatory effect of the 13-cis-retinoic acid and long-lasting remissions. Side effects had not been serious.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000236:Adenoma / Q000188:drug therapy*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007536:Isomerism; D015474:Isotretinoin; D008297:Male; D008875:Middle Aged; D012393:Rosacea / Q000188:drug therapy*; D012626:Sebaceous Gland Neoplasms / Q000188:drug therapy*; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use*
D014212:Tretinoin; D015474:Isotretinoin
Orale 13-cis-Retinsäure-Therapie bei Adenoma sebaceum symmetricum und schwersten Akne- und Rosazeaformen.